Jiangsu Gdk Biological Technology Co., Ltd (SHA:688670)
15.76
+0.36 (2.34%)
Jul 15, 2026, 3:00 PM CST
SHA:688670 Revenue
Jiangsu Gdk Biological Technology had revenue of 898.80K CNY in the quarter ending March 31, 2026, a decrease of -74.05%. This brings the company's revenue in the last twelve months to 110.32M, up 39.21% year-over-year. In the year 2025, Jiangsu Gdk Biological Technology had annual revenue of 112.88M with 39.70% growth.
Revenue (ttm)
110.32M
Revenue Growth
+39.21%
P/S Ratio
17.60
Revenue / Employee
282.87K
Employees
390
Market Cap
1.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 112.88M | 32.08M | 39.70% |
| Dec 31, 2024 | 80.80M | -53.79M | -39.96% |
| Dec 31, 2023 | 134.59M | -183.89M | -57.74% |
| Dec 31, 2022 | 318.49M | -73.79M | -18.81% |
| Dec 31, 2021 | 392.27M | -196.83M | -33.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.13B |
| Shandong Sito Bio-technology | 1.09B |
| Zhejiang East Asia Pharmaceutical | 1.01B |
| Guiyang Xintian Pharmaceutical | 735.18M |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |
| Tiansheng Pharmaceutical Group | 530.52M |
| Cabio Biotech (Wuhan) | 418.18M |
| Suzhou Fushilai Pharmaceutical | 412.51M |